Search Results
Studying speech perception with different acoustic playback methods
The purpose of this study is to examine how different acoustic playback methods affect the understanding of speech.
There will be one in person session in the Hammond building on University Park Campus. The session will last approximately 1 - 1.5 hours. During this session you will listen to audio recordings over headphones and loudspeakers and will complete a speech intelligibility task - you will need to listen for a certain talker and indicate what the talker said. You will receive training before completing the task. You will wear a sensor on one of you fingers that measures your physiological response including heart rate, body temperature, and perspiration for the duration of the session. When wearing the headphones, your head motion will be tracked. A hearing screening will be done at the start of your scheduled time to confirm eligibility for the study. If you don't meet the requirements, you will receive $5 in cash. If you do meet the requirements and complete the study, you will receive $25 in cash.
$25
A native speaker of American English.
Does not have any diagnosed speech, language, or hearing disorders.
Must be able/willing to have physiological devices placed on their head and wrist for accurate data collection.
Have normal or corrected-to-normal vision
Not a native speaker of American English.
Have any diagnosed speech, language, or hearing disorders.
Not able/willing to have physiological devices placed on their head and wrist for accurate data collection.
Not have normal or corrected-to-normal vision
REGIMEN-SPECIFIC APPENDIX I FOR NUZ-001
NUZ-001 ((S)-monepantel) is a synthetic drug that aims to stimulate a natural cleaning mechanism called autophagy that removes the build-up of waste products in cells. In patients with ALS, autophagy can be impaired, leading to the toxic build-up of waste products, causing the motor neuron to die.
If you qualify for this regimen, you will be randomly assigned to take either active study drug or placebo. This is a double-blind, placebo-controlled study. This means that participants are selected by chance (like tossing a coin) to be in 1 of 2 groups – this is called “randomization.” “Double-blind” means that neither you, the study doctor, nor any of the study staff will know whether you are receiving active drug or placebo. However, your study doctor can find out in case of an emergency. The placebo looks and feels exactly like the study drug but contains no active drug.
$700
Prior history of drug-induced liver injury (DILI)
Family history of SOD1 or VCP-associated ALS or known SOD1 or VCP mutation via genetic testing or self-report
Use of any prohibited medications as outlined in Section 5.9 within 30 days prior to Baseline or anticipated use during the study treatment period
Participants who are taking Nuedexta® and have a prolonged Fridericia-corrected QT (QTcF) interval (QTcF > 450 ms (males) or > 470 ms (females)) at Master Protocol Screening
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
The purpose of this voluntary research study is to evaluate the effects of pumitamig compared with placebo in combination with chemotherapy.
Participants must come to all study visits, take the medication as instructed, tell the study how you are feeling and tell the study team about any medications you are taking, especially over the counter medications.
$50.00 per visit
Are considered ineligible for combination treatment with a monospecific PD(L)1 targeting immunotherapy plus chemotherapy as per their tumor PD-L1 expression status.
Have confirmed locally recurrent inoperable or metastatic TNBC, or ER-low, HER2-negative breast cancer documented prior to trial screening as part of standard of care.
Have at least one measurable lesion as the targeted lesion based on RECIST v1.1.
Have provided a tissue sample, archival or fresh, during the screening period
Have received prior treatment with a PD(L)-1/VEGF bispecific antibody.
Are pregnant or breastfeeding or are planning pregnancy or planning to father children during the trial or within 6 months after the last dose of pumitamig or placebo.
Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the trial,
Have received allogeneic hematopoietic stem cell transplantation or organ transplantation.
MOMENTUM-1: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF [177LU]LU-DOTATATE IN ADULTS WITH PROGRESSIVE INTRACRANIAL GRADE 1-3 MENINGIOMA
We are doing this study because we want to find out if this study therapy is better or worse than the usual drug therapy for your meningioma. The usual is defined as the standard of care most people get for meningiomas that have come back after treatment.
Your participation in this study will last a maximum of 4 years. If you are randomized to Group 1, your study doctor will discuss the usual drug treatment options with you and you will be followed for up to 24 months. Your total participation could be up to 14 research visits which includes up to 6 months of treatment and 18 months of follow up. If your meningioma progresses within the first 12 months, you may switch to Group 2 and the 24 month follow-up clock restarts. If you are randomized to Group 2, you will receive the study drug once every 4 weeks for up to 4 times (total duration of 3 months). If after 4 doses your meningioma has not grown and you are tolerating the study treatment, you may receive 2 more doses of study drug. Your total participation for Group 2 could be up to 14 research visits which includes up to 6 months of treatment and 18 months of follow up.
Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan
Progression of disease determined by local radiology review
Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
Adequate organ and bone marrow function
Patients with radiation-associated meningiomas.
Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column.
Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide.
An active malignancy ≤ 3 years.
PSCI# 26-013 A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
To see how well amivantamab works in immunosuppressed patients with cutaneous squamous cell cancer.
Participants will need to come to the clinic every week for the first four weeks of treatment while you are getting the amivantamab. After that you will come in monthly for treatment. You will continue treatment until it stops working, you no longer want to participate in the trial or the doctor\ thinks it is no safe for you to participate. Make sure to tell the study team how you are feeling and any medications that you er taking.
Participants must have CLL, acute leukemia, lymphoma, multiple meyloma, recent organ transplant, autoimmune disease
Participant must be ≥ 18 years old
The Genome Integrity and Epigenome of Sperm from Men with Recurrent Pregnancy Loss
Semen sperm samples will be collected from the male partner of couples that experience recurrent pregnancy loss. DNA analysis will be performed on the samples to investigate potential male factor causes of recurrent pregnancy loss.
Male partners of couples with recurrent pregnancy loss will be asked to provide two semen samples. The male partner will also be asked to complete the Charleston Co-Morbidity index at the time of the patient visit.
Paternal age 18-40 years old at losses
Maternal age 18-40 years old at losses
A couple undergoing ASRM evidenced based work-up or work-up already performed
Actively trying to conceive
Co-morbidities in female partner including diabetes, autoimmune diseases, and BMI >40
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (ILD-PRO) Registry
This is an observational registry with the goal of collecting data and biological samples that will support future research studies for Idiopathic Pulmonary Fibrosis (IPF) and other chronic fibrosing ILDs.
Participants will be required to answer questionnaires and have blood drawn every 6 months at their routine pulmonary clinic visits. Participants' de-identified health information will be entered into the a registry database by the study team every 6 months.
Age >/= 21 years
Currently listed for lung transplantation at the time of enrollment
Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
.PSCI# 25-163 The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemotherapy For Early Rectal Cancer
This is an international multi-centre, phase 3 randomized non-inferiority trial comparing induction FOLFOX/CAPOX chemotherapy followed by transanal endoscopic surgery (TES) to chemoradiation (chemoRT) followed by transanal endoscopic surgery (TES) in patients with cT1-T3ab*/N0 pMMR rectal adenocarcinoma.
Participants will receive chemotherapy with or without radiation for approximately 12 weeks. Once treatment is completed, they will have tests to see if the cancer is gone. Depending upon the scan results, the participant may have surgery or watch and wait. Total participant ime would be five years.
cN0 stage based on pelvic MRI – including absence of radiographic evidence of mesorectal nodal metastasis, tumour deposits or extramural venous invasion (EMVI).
M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis.
Mid to low-lying tumour eligible for transanal excision in the opinion of the treating surgeon.
Medically fit to undergo radical TME surgery as per treating surgeon’s decision.
Patients with visible pelvic sidewall nodes on MRI.
Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration.
Prior treatment for rectal cancer.
Any contra-indications to undergo MRI imaging.
Effects of Reduced Vision and Light Touch on Walking Balance
This study will assess how healthy adults use vision and light touch at their fingertips (for example, as you might lightly touch a handrail) to help them maintain balance while they walk.
If you agree to participate, we will ask you to come to the lab in Rec Hall on Penn State's campus. First, we will ask you to complete a health history questionnaire, visual assessments, and physical assessments. We will also make measurements of your height, weight, and blood pressure. These assessments will help us determine if you are eligible to continue in the remainder of the study. After screening, if you meet the eligibility criteria, we will ask you to walk on various paths on a virtual reality treadmill under various conditions. Your task will be to walk normally and look forward in each condition. Treadmill walking will take less than an hour and breaks will be given as needed.
$20.00
Normal vision without or with glasses/contacts
Able to walk unassisted at least 5 minutes
Body mass index (BMI) > 30 kg/m^2
Health conditions or medications that might impair your balance
The Effects of Acute Hyperglycemia on Cardiovascular Responses to Exercise in Healthy Adults and Individuals with Prediabetes and Type 2 Diabetes
Blood sugar spikes (i.e., acute hyperglycemia) are a common occurrence in individuals with metabolic dysfunction (i.e., prediabetes and type 2 diabetes). Previous research has shown that blood sugar spikes can temporarily worsen blood vessel health and function in healthy adults and individuals with metabolic dysfunction. Additionally, previous research suggests that blood sugar spikes can lead to elevated exercise blood pressure responses in healthy, college-aged adults. However, little is known about the impact of blood sugar spikes on cardiovascular responses to exercise (i.e., blood pressure and blood flow) in healthy middle-aged adults and individuals with metabolic dysfunction. The purpose of this study is to determine the impact of blood sugar spikes on cardiovascular responses during handgrip exercise. Participants will report to the lab for 3 sessions. Session 1 will be a baseline/control session. During sessions 2 and 3, participants will be randomly assigned to consume either a high-glucose beverage (75 g), or a high-fructose beverage (75 g). Glucose causes blood sugar spikes whereas fructose does not. Both before and after the consumption of either beverage, blood pressure, blood flow, and muscle oxygenation responses to handgrip exercise will be measured.
The study will include 3 sessions. Participants will report to the lab for 3 sessions. Session 1 will be a control session. During sessions 2 and 3, participants will be randomly assigned to drink a high-glucose beverage, or a high-fructose beverage. The measurements for this study will include body composition measurements, questionnaires, finger prick blood sampling to measure blood sugar levels, heart rate and blood pressure measurements, measurements of blood vessel health, and handgrip exercise with the measurement of blood pressure, blood flow, and muscle oxygen levels.
$75
Individuals with normal blood sugar levels
Individuals with prediabetes
Individuals with type 2 diabetes
Insulin medication use
Diabetic neuropathy
Women who are pregnant
Diagnosed type 1 diabetes
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
The study is being done to learn how well tirabrutinib (investigational drug) works against cancer as compared to the combination of rituximab and temozolomide (comparator) in participants with PCNSL. We will also learn more about the safety of tirabrutinib and look at how tirabrutinib may affect the body.
To be in this study: o You must have confirmed PCNSL that has come back after treatment (relapsed) or has not improved with prior treatment (refractory) o You must have received methotrexate previously. You will be required to only take the assigned study drug to treat your cancer while on this study. If you believe that you will want to receive other therapy for your cancer, you should not participate in this study. You must agree to not participate in any other study while participating in this study or take any other therapy for your cancer while participating in this study.
Participants aged ≥18 years on the day of consenting to the study
Relapsed or refractory B-cell PCNSL with at least 1 prior HD-MTX–based therapy for PCNSL
Pathology report confirming the diagnosis of B-cell PCNSL
Life expectancy of at least 3 months
Participants who have contraindications to MRI or use of MRI contrast
Participants with non-B cell PCNSL
Participants with systemic presence of lymphoma
Refractory to temozolomide with or without rituximab containing regimens (eg, methotrexate-temozolomide-rituximab) in the last PCNSL treatment
AALL2131: An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib.
The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib. All patients on this study will receive the immunotherapy medicine blinatumomab in addition to chemotherapy plus dasatinib or imatinib. The treatment on this study takes about 2 years. It is divided into 7-8 phases of therapy. Participants will be asked to do some optional tests that will help to learn more about their immune system. To do these tests, we would like to take about 2 teaspoons (6-10 ml) of peripheral blood and about 1 teaspoon (3-5 ml) of bone marrow (at the time of standard procedures) at different time points. These tests will not require additional needle sticks or additional procedures. There will also be optional collection of bone marrow and/or blood for banking for future research.
Newly-diagnosed Ph+ or ABL-class Ph-like B-ALL
Patients with Ph+ B-ALL must have previously started Induction therapy
ABL-class Ph-like B-ALL who are CNS2 or CNS3 at end of Induction phase
ALL developing after a previous cancer treated with cytotoxic chemotherapy
RNA and DNA Sequencing in Dermatomyositis (DM) Patients
The purpose of this study is to find out if gene expression signatures are different in people with cancer associated dermatomyositis (CAM) and CAM negative (CAM-) patients. Dermatomyositis (DM) participants will provide up to 3 blood samples and 2 skin samples for testing, including testing that has to do with genes. Control participants (those who do not have a skin condition) will provide up to 2 skin samples for testing, including testing that has to do with genes.
Only control subjects are being recruited through StudyFinder. There will be one in-person visit where up to 2 skin samples will be collected using a punch biopsy.
$50.00 per skin sample
Aged 18 years and older
Have dermatomyositis (DM) or any other systemic inflammatory disease (ex: lupus, eczema, scleroderma, rheumatoid arthritis, etc.)